Ondine Biomedical Inc - Vancouver, Canada-based life sciences company focused on photodisinfection-based therapies - Says the Ottawa Hospital in the Canadian capital has chosen Ondine's photodisinfection technology for a three-month pilot evaluation of a non-antibiotic protocol to prevent infections in spine surgery patients. Says nasal decolonisation is recommended by World Health Organization to reduce surgical site infections in spine surgeries. Ondine says the technology has already been deployed in a few Canadian hospitals, where it has reduced post-operative infection rates for spine surgeries by 78%.
Photodisinfection is a low-cost therapy that improves patient outcomes reducing readmission rates and costs by eliminating the pathogens they are carrying.
Chief Executive Officer Carolyn Cross says: "Following Covid-19, it is more important than ever to reduce patient readmission rates given the large surgery backlogs at all Canadian hospitals. Nasal decolonisation has long been recommended by the World Health Organization for complex surgeries. Steriwave nasal photodisinfection enables fast, broad-spectrum efficacy, resulting in significant improvements to patient outcomes, cost savings, and bed capacity."
Current stock price: 33.70 pence
12-month change: down 42%
By Xindi Wei; xindiwei@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Ondine Biomed (OBI)